We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| C4x Discovery Holdings Plc | LSE:C4XD | London | Ordinary Share | GB00BQQ2RV18 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 12.00 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 10.30 | 10.80 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 12.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 26/4/2024 | 07:00 | UK RNS | AIM Cancellation - C4X Discovery Holdings plc |
| 25/4/2024 | 20:57 | ALNC |  TRADING UPDATES: Norcros sells Johnson Tiles UK; Trifast trading well |
| 25/4/2024 | 07:00 | UK RNS | C4X Discovery Holdings PLC Last day of dealings and update on cancellation |
| 23/4/2024 | 15:35 | UK RNS | C4X Discovery Holdings PLC Holding(s) in Company |
| 19/4/2024 | 18:00 | UK RNS | FTSE Russell C4X Discovery Holdings |
C4x Discovery (C4XD) Share Charts1 Year C4x Discovery Chart |
|
1 Month C4x Discovery Chart |
Intraday C4x Discovery Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 09/7/2024 | 11:30 | C4X Discovery Holdings plc | 3,144 |
| 03/1/2024 | 08:46 | c4xd Astra Zeneca $11m Milestone payment | 3 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 30/4/2024 12:33 by takeiteasy The first auction in the Ordinary Shares is scheduled to close on Thursday, 13th June 2024, subsequent auctions are to take place on a quarterly basis thereafter. Shares were admitted to trading at 12 pence per share (the last traded price on AIM). |
Posted at 30/4/2024 06:32 by takeiteasy Never been down this road before, but speaking to asset match they are now aware of the need to organise thr first trading window which allows buys and sells to be put on the order book over an agreed period with a view to settling at the end at an agreed fair price. The punters have a chance to view what the bid/offer prices are being asked for and so determine if this first window is one that provides the right price to sell or not.Otherwise you wait for the next one - my preference is to wait for the next results and see if they are managing to make more progress unshackled from LSE - dyor etc. Not clear yet how often these trading windows are going to be set - let's see what happens. |
Posted at 15/4/2024 22:07 by davemac3 well that's it, vote for taking private confirmed. What are folks doing with their shares? I have some in an iweb ISA and will probably get them out as a share certificate. I also have some in a HL SIPP which I may leave there for now but move them eventually to a SIPP provider that deals with asset match. |
Posted at 09/4/2024 13:02 by takeiteasy 9 April 2024 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, was informed on 8 April 2024 that Clive Dix, Executive Chairman of the Company, purchased 485,320 ordinary shares of 0.01 pence each ("Ordinary Shares") in the Company at a price of 10.3 pence per share.Following this purchase of shares, Clive Dix has a beneficial interest in 2,071,809 Ordinary Shares, representing approximately 0.82 per cent. of the Company's issued share capital. nice timing :) lols |
Posted at 27/3/2024 20:47 by timbo003 >>>>luck"Best option will be to short these since could be 0p when they delisted." I suspect that if you were to go short and the company delists, the counterparty to your spreadbet would want you to deliver the shares when the bet expires. Not an easy task if they are delisted, although I note that the RNS states that the directors intend to set up a matched bargain facility following delisting, if they do, you would have to wait for a willing seller to come along before you could buy shares and the offer price then could be quite a bit higher than it is now 😮 |
Posted at 27/3/2024 07:58 by nigelpm So the announcement will see share price fall materially further - ironic! |
Posted at 06/1/2024 06:54 by takeiteasy UPDATE: Dr Julie Simmonds at Panmure Gordon commented: “C4XD has received an $11m milestone payment from AstraZeneca. We update our estimates. The payment, in addition to the divestment of the Orexin programme in July which generated £16m, means we expect the company to end the year (July) with Net Cash of £22m, the current market capitalization. C4XD is very good value with a strong drug development engine; there are few companies which have successfully developed and out-licensed three differentiated products. We reiterate our BUY recommendation.̶hxxps://www.thebusin hxxps://www.lgbco.co |
Posted at 05/1/2024 14:41 by mirabeau DM - todayIt’s fair to say C4X Discovery had a fantastic start with the shares advancing 113 per cent over the foreshortened trading week after drug giant AstraZeneca delivered an $11million post-Christmas windfall. It came in the form of what the experts call a ‘milestone payment’ under a $402million deal with Anglo-Swedish giant, which has licensed the right to NRF2 activator, created by C4XD to tackle chronic respiratory disease. Analysts said the payment went further than adding a material sum to the AIM company’s coffers – it provided third-party validation of the technology. 'We see this as an important value inflexion which should reinvigorate sentiment in the share,' said regional broker Shore Capital. 'Moreover, this serves as a timely reminder that C4XD has licensing deals in place with some of the leading developers for its programmes.' |
Posted at 03/1/2024 11:39 by intoodeep News of C4X Discovery Holdings PLC (AIM:C4XD)’s latest payment from AstraZeneca PLC (LSE:AZN) solidifies and validates the company’s place as a skilled drug developer, analysts have said.Following the firm’s update that US$11 million had been received under a deal worth up to US$400 million with AstraZeneca for the NRF2 activator programme, Shore Cap analysts backed aim-listed C4X. “We see this as an important value inflection which should reinvigorate sentiment in the share,” the bank said in a note. “Moreover, this serves as a timely reminder that C4XD has licensing deals in place with some of the leading developers for its programmes.” The deal included an initial upfront payment of US$2 million to C4X and consisted of a series of developmental and commercial milestones. Under this, C4X’s NRF2 activator programme has been out-licensed to AstraZeneca with the goal of creating an oral therapy for inflammatory and respiratory diseases. Shore Cap added that its model for C4X suggested fair value of 52p per share, marking a prospective 480% increase on Tuesday’s closing value of 8.7p. “These agreements serve as strong validation of C4XD’s prowess in drug discovery and demonstrate its ability to distil value from assets early in the development process,” the bank said. Indeed, the market reacted positively to the news, with shares in C4X climbing 37% to 11.98p following the news on Wednesday morning. |
Posted at 09/12/2023 17:25 by golden prospect Something very interesting in play, on radar.From AR2022 "During November 2020 £15.0 million (before expenses) was raised via a placing of 99,169,286 ordinary shares and an open offer for 7,973,572 ordinary shares at 14 pence each. In addition, 99,169,286 warrants were issued over ordinary shares, exercisable at 28p per share with an exercise period of 5 years." Clearly an easy short from 2022 @ 45p Stock is tight, Richard Griffiths 22.07%, Polar Capital 17.84%, Lombard Odier 17.29 (have been increasing), Baillie Gifford 8.52%, Canaccord Genuity Wealth Mgt 4.54%, Calculus Capital 3.63%, Herald Investment Mgt 2.67 76.56% accounted for, guess small float leads to distorted share price. Someone ready/building to make an offer ? |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
.png){kind=logo}
